Navigation Links
New MedPredict Report Highlights Recent Advances in Management of Malignant Hematology
Date:1/15/2010

SCOTTSDALE, Ariz., Jan. 15 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing therapies to treat hematologic malignancies.  These reports are based on primary interviews conducted with hematologists from North America immediately following the American Society of Hematology (ASH) annual meeting.

This report, entitled "Thought Leader Insight & Analysis – Malignant Hematology," includes analysis of new research in Multiple Myeloma, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Lymphoma, and Chronic Myelogenous Leukemia.  

"This report reflects on and analyzes the most important data presented at ASH, and clarifies the ways these data will change clinical practice," according to Jeff Berk, MedPredict president. "A key focus of the report is Multiple Myeloma (MM), which is being transformed into a chronic, but still life threatening disease.  The most exciting advances presented at ASH included both identifying the most effective combinations for induction therapy, and in establishing a role and practice standard for maintenance therapy in MM."

According to one MM Thought Leader interviewed for this report:  "I think the message was very positive in regards that maintenance matters, choice of induction strategy matters with less toxicity being important, and staying on treatment of some form or another is very critical."

The expert panel also discusses novel compounds in development for various hematologic malignancies, and the hurdles they will need to overcome to become viable options in this market.  

Companies and partnerships mentioned in this report includes: Allos, Ambit, Amgen, Arno Therapeutics, Antisoma, Biogen Idec/Elan, Biotest/ImmunoGen, Bristol-Myers Squibb, Bristol-Myers Squibb/Facet, Celgene, Celgene/Gloucester, Cephalon, ChemGenex, Cyclacel, Eisai, Genmab, Genzyme, Genzyme/Anormed, Genzyme/Bayer HealthCare Pharmaceuticals, Geron/Merck, GlaxoSmithKline, GlaxoSmithKline/Genmab, ImmunoGen, Immunomedics/Nycomed, Incyte, Keryx, Merck, Milteni Biotec, Novartis, Novartis/Vernalis, OXiGENE, PDL Biopharma, Proteolix/Onyx, Rigel, Seattle Genetics, Syndax, and Takeda/Millennium.

This report can be purchased by contacting MedPredict (www.medpredict.com).  

About MedPredict

MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories.  Based on primary interviews with these thought leaders, MedPredict publishes periodic reports to keep clients up-to-date on emerging trends and competitive activity.  The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict

RELATED LINKS
http://www.medpredict.com

'/>"/>

SOURCE MedPredict
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report
2. Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010
3. New Report by BioTrends Research Group To Highlight The Launch Of ACTEMRA (tocilizumab)
4. Does the MS Market Need Another Interferon? Neurologists Provide Insight in the Wave One Report of LaunchTrends: EXTAVIA
5. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
6. BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties
7. Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016
8. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
9. Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition]
10. Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015
11. Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
Breaking Medicine News(10 mins):